Skip to main content
SpringerLink
Log in

Counseling the Patient With Prostate Cancer

The Radiation Oncologist’s Perspective

  • Chapter
Management of Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 176 Accesses

Abstract

Radiation oncologists, like urologists, often spend more time counseling patients with prostate cancer than treating them. Approximately half the radically treated prostate cancer patients in the United States will have some form of radiation as their primary therapy—but how do they make their choice and what are the contemporary recommendations of the radiation oncologist? Fowler et al. (1) performed a survey of over 1000 US radiation oncologists and urologists in 1998, with depressing results. They showed the truly “partisan” nature of our specialties; 93% of surgeons recommended surgery as primary therapy for early-stage prostate cancer, and 72% of radiation oncologists recommended radiation. I believe that sufficient data have now emerged to allow both sides to be more “reasonable” and to agree on recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fowler FJ, Collins MN, Albertsen PC, Zietman AL, Elliot D, Barry MJ. A comparison of the treatment recommendations for men with clinically localized prostate cancer by urologists and radiation oncologists. JAMA 2000; 283: 3217–3222.

    Article  PubMed  Google Scholar 

  2. Holmberg L, Bill-Axelson A, Helgesen F, and the Scandinavian Prostatic Cancer Study Group. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–789.

    Google Scholar 

  3. Warner J, Whitmore WF. Expectant management of clinically localized prostatic cancer. J Urol 1994; 152: 1761–1765.

    PubMed  CAS  Google Scholar 

  4. Johansson J-E, Holmberg L, Johansson S, Bergstrom R, Adami H-O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467–471.

    Article  PubMed  CAS  Google Scholar 

  5. Koppie TM, Grossfeld GD, Miller D, et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from the CaPSURE database. J Urol 2000; 164: 81–88.

    Article  PubMed  CAS  Google Scholar 

  6. Zietman AL, Thakral HJ, Wilson L, Schellhammer PF. Conservative management of prostate cancer in the PSA era:watchful waiting or delayed therapy? J Urol 2001; 166: 1702–1706.

    Article  PubMed  CAS  Google Scholar 

  7. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am 1997; 24: 395–402.

    Article  PubMed  CAS  Google Scholar 

  8. Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997; 50: 93–99.

    Article  PubMed  CAS  Google Scholar 

  9. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158: 1441–1444.

    Article  PubMed  CAS  Google Scholar 

  10. Amling CL, Blute ML, Bergstralh EJ, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101–105.

    Article  PubMed  CAS  Google Scholar 

  11. American Society for Therapeutic Radiology and Oncology consensus panel. Consensus statement: guidelines for PSA following radiotherapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035–1041.

    Google Scholar 

  12. D’Amico AV, Chen MH, Oh-Ung J, et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 2002; 54: 436–441.

    Article  PubMed  Google Scholar 

  13. Kupelian P, Potters L, Ciezki J, Reddy C, Reuther A, Klein E. Radical prostatectomy, external beamradiotherapy 27Gy, external beam radiotherapy 72Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–2 prostate cancer. Int J Radiat Oncol Biol Phys 2002; 54: 38–43.

    Article  Google Scholar 

  14. Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after transperineal sonographyguided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma. Cancer 1998; 83: 989–1001.

    Article  PubMed  CAS  Google Scholar 

  15. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy from prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 839–850.

    Article  PubMed  CAS  Google Scholar 

  16. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582–1592.

    Article  PubMed  CAS  Google Scholar 

  17. Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001; 166: 494–499.

    Article  PubMed  CAS  Google Scholar 

  18. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 1999; 353: 267–272.

    Article  PubMed  CAS  Google Scholar 

  19. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000; 18: 3904–3911.

    PubMed  CAS  Google Scholar 

  20. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P. Late normal tissue sequelae in the second decade following high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 2002; 167: 123–126.

    Article  PubMed  CAS  Google Scholar 

  21. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51 (3): 614–623.

    Google Scholar 

  22. Sacco DE, Daller M, Grocela JA, Babayan RK, Zietman AL. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. Br J Urol 2003; 91: 345–349.

    Article  CAS  Google Scholar 

  23. Davis JW. Kuban DA. Lynch DF. Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001; 166: 947–952.

    Article  PubMed  CAS  Google Scholar 

  24. Taghian A, De Vathaire F, Terrie P, et al. Long term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 1991; 21: 361–367.

    Article  PubMed  CAS  Google Scholar 

  25. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88: 398–406.

    Article  PubMed  CAS  Google Scholar 

  26. Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 2000; 89: 1792–1799.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Anthony Zietman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Urology Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

    Eric A. Klein MD (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Zietman, A. (2004). Counseling the Patient With Prostate Cancer. In: Klein, E.A. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-776-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-776-5_24

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5711-8

  • Online ISBN: 978-1-59259-776-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation